Scott M. Wilhelm
Bayer Pharmaceuticals Corporation
West Haven
Connecticut 06516
USA
Name/email consistency: high
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R.A., Schwartz, B., Simantov, R., Kelley, S. Nat. Rev. Drug. Discov (2006)
- BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Wilhelm, S.M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., Cao, Y., Shujath, J., Gawlak, S., Eveleigh, D., Rowley, B., Liu, L., Adnane, L., Lynch, M., Auclair, D., Taylor, I., Gedrich, R., Voznesensky, A., Riedl, B., Post, L.E., Bollag, G., Trail, P.A. Cancer Res. (2004)
- BAY 43-9006: preclinical data. Wilhelm, S., Chien, D.S. Curr. Pharm. Des. (2002)
